(Q33970367)

30 July 2017

1 reference

title

Vascular drugs in the new millennium (English)

1 reference

30 July 2017

S G Frangos

1

1 reference

30 July 2017

A H Chen

series ordinal

2

1 reference

30 July 2017

B Sumpio

series ordinal

3

1 reference

30 July 2017

language of work or name

1 reference

1 July 2000

1 reference

Journal of the American College of Surgeons

30 July 2017

published in

1 reference

30 July 2017

volume

191

1 reference

30 July 2017

issue

1

1 reference

30 July 2017

page(s)

76-92

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

30 July 2017

1 reference

7 January 2021

Final report on the aspirin component of the ongoing Physicians' Health Study

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Blockade of Platelet GPIIb/IIIa Receptors as an Antithrombotic Strategy

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Antiplatelet monoclonal F(ab')2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Cyclic flow variations after coronary angioplasty in humans: clinical and angiographic characteristics and elimination with 7E3 monoclonal antiplatelet antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Compl

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

1 reference

7 January 2021

Low molecular weight heparins: current use and indications

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin iii and by gel filtration

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Low-molecular-weight heparins

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery. A placebo controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement. A randomized trial. The German Hip Arthroplasty Trial (GHAT) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Prevention of thromboembolism in spinal cord injury: role of low molecular weight heparin

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Use of low molecular weight heparin in preventing thromboembolism in trauma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Low-molecular-weight heparin in the treatment of patients with venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Low molecular weight heparin(oid)s. Clinical investigations and practical recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Recombinant hirudin: genetic engineering and structure analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

The development of hirudin as an antithrombotic drug

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Direct thrombin inhibition superior to heparin during and after thrombolysis: dose, duration, and drug

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Antithrombins: their potential as antithrombotic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Current issues in management of thromboses

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Thrombolysis or peripheral arterial surgery: phase I results. TOPAS Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Evaluation of thrombolytic agents.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

New plasminogen activators: a clinical review.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Combination therapy for acute myocardial infarction: glycoprotein IIb/IIIa inhibitors plus thrombolysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Results of a Prospective Randomized Trial Evaluating Surgery Versus Thrombolysis for Ischemia of the Lower Extremity The STILE Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Tissue plasminogen activator for acute ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Anti-streptokinase antibodies inhibit fibrinolytic effects of anistreplase in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Short- and long-term comparative study of anistreplase versus streptokinase in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Halving of mortality at 1 year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT)

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Magnitude of benefit from earlier thrombolytic treatment in acute myocardial infarction: new evidence from Grampian region early anistreplase trial (GREAT)

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Myocardial salvage with early anistreplase treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Pharmacologic management of peripheral vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Effect of pentoxifylline on erythrocyte membrane and plasma lipids

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Pentoxifylline for intermittent claudication. A critical review

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

The effects of pentoxifylline on patients with intermittent claudication

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Pharmacokinetics of multiple-dose oral cilostazol in middle-age and elderly men and women

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900292-1

7 January 2021

10.1016/S1072-7515(00)00292-1

Identifiers

DOI

1 reference

30 July 2017

1 reference